Clinical Trial Update: A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies [Phase 3]

View source ↗

Summary

Phase 3 trial update for canakinumab in systemic juvenile idiopathic arthritis and hereditary periodic fevers; results completed with postings in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Periodic Fevers
• Systemic Juvenile Idiopathic Arthritis

Drugs mentioned

• Canakinumab (canakinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Systemic Juvenile Idiopathic Arthritis, Hereditary Periodic Fevers | Phase 3 | Status: COMPLETED | Results posted: 2020-05-19